EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Recurrent Non-islet Cell Tumor Hypoglycemia Secondary to Hepatocellular Carcinoma: Case Report and Literature Review

Dan He, Hongpeng Gong, Jie Pan, Fangchao Zhu, Xiaofen Jiang, Huang Su iD

Zeitschrift für Gastroenterologie · 2024-05 · 62 (05) · 752-758

DOI: 10.1055/a-2170-1691 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Zeitschrift für Gastroenterologie, online erschienen am 05.10.2023. Verfasst von Dan He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Wenzhou Central Hospital, Wenzhou, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Hypoglycemia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Non-islet cell tumor hypoglycemia (NICTH) is a paraneoplastic syndrome caused by tumors other than insulinoma that is primarily due to excessive production of insulin-like growth factor-II (IGF-II). The prevalence of NICTH is likely underestimated because of a lack of clinical recognition. Patient Concerns A 41-year-old male with massive malignant liver tumors presented with recurrent severe hypoglycemia, weight loss, and liver cirrhosis. Diagnosis NICTH related to IGF-II produced by hepatocellular carcinoma was diagnosed based on clinical symptoms, biochemical tests, and elevated IGF-II/IGF-I ratio.

Intervention

Initial treatment with intravenous glucose and parenteral nutrition showed limited efficacy. Glucocorticoids and recombinant human growth hormone led to progressive improvement in blood glucose levels. Outcome Due to extensive tumor burden and liver failure, surgical resection was not feasible, and the patient ultimately succumbed to refractory hypoglycemia and passed away in two weeks. Lessons Early recognition and diagnosis of NICTH are crucial in patients with recurrent hypoglycemia and large tumors. Surgical resection is the preferred treatment option, but supportive care and pharmacological interventions, such as glucocorticoids and growth hormone, can help manage refractory hypoglycemia. Further research is needed to explore novel treatment options, including anti-IGF-I and -IGF-II neutralizing antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularHypoglycemiaHumansMaleAdultInsulin-Like Growth Factor IIFatal OutcomeParaneoplastic Syndromes

Substanzen

Insulin-Like Growth Factor II

Autor:innen und Institutionen

  • Department of Gastroenterology, Wenzhou Central Hospital, Wenzhou, China.

ORCID-Profile: Huang Su

Zitieren

APA

He, D., Gong, H., Pan, J., Zhu, F., Jiang, X., & Su, H. (2024). Recurrent Non-islet Cell Tumor Hypoglycemia Secondary to Hepatocellular Carcinoma: Case Report and Literature Review. Zeitschrift für Gastroenterologie, 62(05), 752-758. https://doi.org/10.1055/a-2170-1691

Vancouver

He D, Gong H, Pan J, Zhu F, Jiang X, Su H. Recurrent Non-islet Cell Tumor Hypoglycemia Secondary to Hepatocellular Carcinoma: Case Report and Literature Review. Zeitschrift für Gastroenterologie. 2024;62(05):752-758. doi:10.1055/a-2170-1691

BibTeX
@article{He2024,
  author = {He, Dan and Gong, Hongpeng and Pan, Jie and Zhu, Fangchao and Jiang, Xiaofen and Su, Huang},
  title = {Recurrent Non-islet Cell Tumor Hypoglycemia Secondary to Hepatocellular Carcinoma: Case Report and Literature Review},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2024},
  volume = {62},
  number = {05},
  pages = {752--758},
  doi = {10.1055/a-2170-1691}
}
Kostenlos starten →